LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2025.
Third Quarter Fiscal 2025 Summary*:
Revenue was $58.4 million, an increase of 21.1% from the prior year period.
Excluding the negative impact of foreign currency fluctuations, third quarter revenue increased approximately 22.1%;
Revenue in the Americas increased 29.5%, and revenue in Asia/Pacific & Europe decreased 7.2%.
Excluding the negative impact of foreign currency fluctuations, third quarter revenue in Asia/Pacific & Europe decreased approximately 4.7%;
Net income per diluted share was $0.26, versus $0.13 per diluted share a year ago;
Adjusted earnings per diluted share was $0.26, compared to $0.21 a year ago; and
Adjusted EBITDA was $6.4 million compared to $5.1 million a year ago.
* All comparisons are on a year over year basis and compare the third quarter of fiscal 2025 to the third quarter of fiscal 2024, unless otherwise noted.
Steve Fife, President and CEO of LifeVantage said:
“Third quarter results were strong with revenues up 21% year-over-year to $58.4 million, reflecting robust demand for our MindBody GLP-1 System™. We also delivered another quarter of improving profitability including a 210 basis point improvement